ENZAMET Announced as ACTA Trial of the Year 2020

The ANZUP led ENZAMET trial (ANZUP 1304)  was announced as the winner of the 2020 ACTA Trial of the Year Award, the ACTA STInG Award for Excellence in Trial Statistics and the Consumer Involvement Award. A fantastic achievement and the first trial to be awarded all three categories.

ACTA is the national peak body supporting and representing networks of clinician researchers conducting investigator-initiated clinical trials within the Australian healthcare system. The awards are designed to celebrate Australia’s world-leading clinical trials expertise and promote the role, importance and value of clinical trials in Australia.

Professor Ian Davis, ANZUP Chair, accepted the Trial of the Year Award, saying, "I’m honoured to be part of a study that has had such impact for men with metastatic prostate cancer. Professor Christopher Sweeney and I, as co-chairs, have been part of a talented and dedicated international team of researchers, staff, consumers, and most importantly, our trial participants. I could not be prouder than to have the ENZAMET Trial also acknowledged not only as Trial of the Year, but also for its excellence in trial statistics and consumer involvement.”

Prof Ian Davis Accepting Trial of the Year Award

This trial was only made possible because of the following: study co-chairs Professor Ian Davis and Professor Chris Sweeney, the principal investigators, co-investigators, study coordinators, clinical research associates, nurses and data managers, NHMRC Clinical Trials Centre, Cancer Trials Ireland, Canadian Cancer Trials Group, Dana Faber Cancer Institute, our Consumer Advisory Panel, the 83 trial centres both nationally and internationally, and most importantly the 1125 patients involved in the trial. Astellas Pharma provided drug and financial support but was not involved in study conduct or data analysis.

Findings from the ENZAMET trial have shown that hormone therapy with a drug called enzalutamide can improve the survival of some men with advanced, hormone-sensitive prostate cancer, and men with this sort of cancer who receive enzalutamide with standard treatment have a 33% improvement in overall survival and a 60% improvement in progression-free survival, compared to men receiving standard treatment alone.

ENZAMET continues to be recognised both nationally and internationally. Last year the trial featured in the ASCO main plenary session, and these practice changing results generated worldwide interest both through extensive media coverage and the medical community. In 2020 the achievements of this trial continued with ENZAMET featuring in ESMO’s Clinical Practice Guidelines for 2020. Other recognition includes being named in the ASCO Annual Report on Progress Against Cancer and as one of ASCO's Clinical Cancer Advances for 2020.

To read more about the ENZAMET study and results visit

© ANZUP 2021. All rights reserved.